Clinical Trial: Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects with Multiple Sclerosis (MS)


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

Sponsored by:	Abbott Laboratories
Information provided by:	Abbott Laboratories

Condition	Treatment or Intervention	Phase
Multiple Sclerosis Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive	Drug: ABT-874/Human monoclonal antibody against IL-12	Phase II

Inclusion Criteria:

Age between 18-55 years
Diagnosis of active relapsing remitting or secondary progressive multiple sclerosis
At least one relapse within 12 months of screening.
Must be able to walk at least 65 feet with or without assistance
Off Copaxone or interferon therapy for two months prior to screening
Able and willing to learn to self administer weekly injections, or have a designee who will administer study medication
Female participants must use contraceptives while on study drug

Exclusion Criteria:

Patients with the following conditions are not eligible to participate in the study:

Primary progressive multiple sclerosis
Active TB, HIV, Lyme disease, syphillis, Hepatitis B or C, or other active infections
Pregnant or lactating females

Arizona
St. Joseph's Hospital & Medical Center, Phoenix, Arizona, 85013, United States; Recruiting

Lou DiCave 602-406-7711 ldicave@chw.edu
Timothy Vollmer, MD, Principal Investigator

California
UC Davis Medical Center, Sacramento, California, 95817, United States; Recruiting

Janelle Butters 916-734-6276 janelle.adams@ucdmc.ucdavis.edu
Mark Aguis, MD, Principal Investigator

USC Keck School of Medicine, Los Angeles, California, 90033, United States; Recruiting

Pat Gutierrez 323-224-5333 pgutierrez@usc.edu
Leslie Weiner, MD, Principal Investigator

Colorado
Alpine Clinical Reasearch Center, Boulder, Colorado, 80304, United States; Recruiting

Peg Sharp 303-449-7229 peg@alpineresearch.com
George Garmany, MD, Principal Investigator

Florida
University of Miami, Miami, Florida, 33136, United States; Recruiting

Marilyn Martinez 305-243-1088 mmartinez13@med.miami.edu
William Sheramata, MD, Principal Investigator

Georgia
The MS Center of Atlanta, Atlanta, Georgia, 30327, United States; Recruiting

Donna Court 404-351-0205 d.court@mscatl.com
William Stuart, MD, Principal Investigator

Shepherd Center, Atlanta, Georgia, 30308, United States; Recruiting

Ismari Clesson 404-350-7651 ismari_clesson@shepherd.org
Ben Thrower, MD, Principal Investigator

Illinois
University of Chicago Hospitals, Chicago, Illinois, 60637, United States; Recruiting

Mildred Valentine 773-834-1811 mvalenti@neurology.bsd.uchicago.edu
Anthony Reder, MD, Principal Investigator

Consultants in Neurology, Ltd, Northbrook, Illinois, 60062, United States; Recruiting

Catherine Meyer 847-509-0270 dwynnmd@interaccess.com
Daniel Wynn, MD, Principal Investigator

Indiana
Indiana University Hospital, Indianapolis, Indiana, 46202, United States; Recruiting

Lee Hayward 317-274-4030 lhayward@iupui.edu
David Mattson, MD, PhD, Principal Investigator

Michigan
Wayne Steet University, Detroit, Michigan, 48201, United States; Recruiting

Melissa Reznar 313-966-5068 mreznar@med.wayne.edu
Omar Khan, MD, Principal Investigator

Missouri
Washington University School of Medicine, St. Louis, Missouri, 63110, United States; Recruiting

Joanne Lauber 314-362-3371 laugerj@neuro.wustl.edu
Becky Parks, MD, Principal Investigator

New Jersey
University of Medicine & Dentistry of New Jersey, Newark, New Jersey, 07103, United States; Recruiting

Jim Quinless 973-972-7395 quinlessj@umdnj.edu
Stuart Cook, MD, Principal Investigator

New York
University of Rochester Medical Center, Rochester, New York, 14642, United States; Recruiting

Eileen Scheid 585-275-6673 Eileen_Scheid@urmc.rochester.edu
Andrew Goodman, MD, Principal Investigator

Upstate Clinical research, Albany, New York, 12205, United States; Recruiting

Suzanne Alterman 518-533-1500 Ext. x 546 salterman@upstateneurology.com
James Storey, MD, Principal Investigator

North Carolina
Carolinas Medical Center, Charlotte, North Carolina, 28203, United States; Recruiting

Priscilla Russo 704-446-1910 priscilla.russo@carolinashealthcare.org
Michael Kauffman, MD, Principal Investigator

Ohio
Ohio State University, Columbus, Ohio, 43210, United States; Recruiting

Megan Nussbaum 614-293-4964 nussbaum-1@medctr.osu.edu
Kottil Rammohan, MD, Principal Investigator

Pennsylvania
Lehigh Valley Hospital, Allentown, Pennsylvania, 18103, United States; Recruiting

Joanne Rodgers 610-402-9004 joanne.rodgers@lvh.com
Alexander Rae-Grant, MD, Principal Investigator

Texas
University of TexasHouston Health Science Center, Houston, Texas, 77030, United States; Recruiting

Myrna Koh 713-500-7045 myrna.koh@uth.tmc.edu
Stanley Brod, MD, Principal Investigator

Washington
MS Hub Medical Group, Seattle, Washington, 98101, United States; Recruiting

Jerrie Sims 206-262-0110 jsims@mshub.org
Craig Smith, MD, Principal Investigator